Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05814835 | First in Human Study of 68Ga/64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors | completed | Phase 1 | 14 | Chinese PLA General HospitalOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT04944888 | GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid Tumor | completed | Phase 1 | 31 | Chinese PLA General HospitalOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05793957 | Use of Virtual Reality Goggles During Chemotherapy Infusion to Reduce Anxiety-Related Symptoms | completed | N/A | 50 | OHSU Knight Cancer InstituteOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT03463473 | A Phase I Study of MSB2311 in Advanced Solid Tumors | completed | Phase 1 | 42 | Suzhou Transcenta Therapeutics Co., Ltd.INDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
| NCT04272944 | A Study of MSB2311 in Advanced Solid Tumors | completed | Phase 1 | 42 | Suzhou Transcenta Therapeutics Co., Ltd.INDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
| NCT01946074 | A Study of ABT-165 in Subjects With Solid Tumors | completed | Phase 1 | 101 | AbbVieINDUSTRY | 1 | Dec 15, 2023 | clinicaltrials |
| NCT04365413 | A Feasibility Study for the Use of Multispectral Optoacoustic Tomography in the Detection of Tumors(OU-SCC-MSOT) | completed | N/A | 54 | University of OklahomaOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT02030067 | Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies | completed | Phase 1 / Phase 2 | 127 | Processa PharmaceuticalsINDUSTRY | 1 | Dec 6, 2023 | clinicaltrials |
| NCT03229278 | Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | completed | Phase 1 | 14 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT05412420 | Artificial Intelligence to Search for Abnormalities in Ambulatory Cancer Patients(IASAAC) | completed | N/A | 500 | Institut de Cancérologie de LorraineOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT02923947 | Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment | completed | Phase 1 | 16 | AstraZenecaINDUSTRY | 3 | Nov 27, 2023 | clinicaltrials |
| NCT03831295 | SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies | completed | Phase 1 | 12 | Ronald LevyOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT04491409 | Perioperative Care in the Cancer Patient -1, ARCA-1 Study | completed | — | 229 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT04830501 | Study of the of the Safety and Tolerability of TT-00434 in Patients With Advanced Solid Tumors | completed | Phase 1 | 11 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT03784677 | A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors | completed | Phase 1 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT03810742 | Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors | completed | Phase 1 | 44 | PharmaEngineINDUSTRY | 1 | Nov 18, 2023 | clinicaltrials |
| NCT05017623 | A Study to Evaluate YH003 in Subjects With Advanced Solid Tumors | completed | Phase 1 | 10 | Eucure (Beijing) Biopharma Co., LtdINDUSTRY | 1 | Nov 18, 2023 | clinicaltrials |
| NCT02729298 | First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors | completed | Phase 1 | 177 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 14, 2023 | clinicaltrials |
| NCT03429218 | First-in-human Study of Oral TP-0184 in Patients With Advanced Solid Tumors | completed | Phase 1 | 24 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 14, 2023 | clinicaltrials |
| NCT03715504 | Study of TP-3654 in Patients With Advanced Solid Tumors | completed | Phase 1 | 22 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 14, 2023 | clinicaltrials |
| NCT03941262 | Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy | completed | Phase 1 | 27 | NKGen Biotech, Inc.INDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT02432326 | A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 147 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 8, 2023 | clinicaltrials |
| NCT05914142 | Study on the Safety and Effectiveness of Varian ProBeam Proton Therapy Equipment in the Treatment of Solid Tumors | completed | N/A | 47 | Guangzhou Concord Cancer CenterOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT04811781 | Epidemiological Features and Clinical Course of COVID -19 Infection in Cancer Patients: The Rovid Study | completed | — | 761 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT04788147 | Performance and Safety of Biology-Guided Radiotherapy Using the RefleXion Medical Radiotherapy System (BIOGUIDE-X)(BIOGUIDE-X) | completed | N/A | 30 | RefleXion MedicalINDUSTRY | 1 | Oct 31, 2023 | clinicaltrials |
| NCT02054806 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28) | completed | Phase 1 | 477 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 30, 2023 | clinicaltrials |
| NCT04247126 | A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors | completed | Phase 1 | 105 | Syros PharmaceuticalsINDUSTRY | 1 | Oct 27, 2023 | clinicaltrials |
| NCT04475523 | Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies | completed | Phase 1 | 26 | Curis, Inc.INDUSTRY | 2 | Oct 27, 2023 | clinicaltrials |
| NCT02644460 | Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors(AflacST1501) | completed | Phase 1 | 53 | Emory UniversityOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT04162327 | A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor | completed | Phase 1 | 55 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Oct 24, 2023 | clinicaltrials |
| NCT03274661 | Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors | completed | Phase 2 | 52 | Baptist Health South FloridaOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT02304458 | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | completed | Phase 1 / Phase 2 | 140 | National Cancer Institute (NCI)NIH | 2 | Oct 17, 2023 | clinicaltrials |
| NCT02780804 | Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT03099109 | A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors | completed | Phase 1 | 209 | Eli Lilly and CompanyINDUSTRY | 4 | Oct 17, 2023 | clinicaltrials |
| NCT03253679 | AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT02718911 | A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors | completed | Phase 1 | 72 | Eli Lilly and CompanyINDUSTRY | 4 | Oct 16, 2023 | clinicaltrials |
| NCT03188965 | First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas | completed | Phase 1 | 229 | BayerINDUSTRY | 7 | Oct 11, 2023 | clinicaltrials |
| NCT02897375 | Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors | completed | Phase 1 | 71 | Emory UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT03017833 | Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers | completed | Phase 1 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT00138216 | Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors | completed | Phase 1 | 42 | Children's Oncology GroupNETWORK | 2 | Oct 2, 2023 | clinicaltrials |
| NCT01827384 | MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations | completed | Phase 2 | 208 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2023 | clinicaltrials |
| NCT02095132 | Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 76 | National Cancer Institute (NCI)NIH | 2 | Sep 26, 2023 | clinicaltrials |
| NCT02793466 | Durvalumab in Pediatric and Adolescent Patients | completed | Phase 1 | 15 | Leo MascarenhasOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT00648648 | A Dose Escalation Study of Adavosertib (MK-1775) in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001) | completed | Phase 1 | 206 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 21, 2023 | clinicaltrials |
| NCT04346381 | Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor | completed | Phase 2 | 233 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 18, 2023 | clinicaltrials |
| NCT01376505 | Vaccine Therapy in Treating Patients With Metastatic Solid Tumors | completed | Phase 1 | 65 | Robert WesolowskiOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT03953235 | A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens | completed | Phase 1 / Phase 2 | 39 | Gritstone bio, Inc.INDUSTRY | 1 | Sep 13, 2023 | clinicaltrials |
| NCT04357756 | A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors | completed | Phase 1 | 29 | Eucure (Beijing) Biopharma Co., LtdINDUSTRY | 1 | Sep 13, 2023 | clinicaltrials |
| NCT04912466 | IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors. | completed | Phase 1 | 61 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Sep 6, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Dec 20, 2023source: clinicaltrials